학술논문
A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma
Document Type
Article
Author
Flümann, Ruth; Nieper, Pascal; Lohmann, Tim; Kisis, Ilmars; Peifer, Martin; Abedpour, Nima; Thomas, Roman; Kochanek, Moritz; Pelzer, Benedikt; Beleggia, Filippo; Buettner, Reinhard; Lohneis, Philipp; Persigehl, Thorsten; Hallek, Michael; Calado, Dinis Pedro; Pasqualucci, Laura; von Tresckow, Bastian; Chapuy, Björn; Jachimowicz, Ron; Reinhardt, Christian; Knittel, Gero
Source
Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p712-712, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. Both biologically and clinically, DLBCL represents a highly heterogeneous disease. DLBCL has been subdivided into germinal center B cell (GCB)-like and activated B cell (ABC)-like DLBCL, on the basis of gene expression profiling, which separates DLBCL according to the presumed cell of origin (COO). This COO-based classifier distinguishes sub-entities displaying distinct biological features, pathogenesis and clinical response to frontline therapy.